Drug
Valemetostat
Valemetostat: highest development phase Phase 2, developed by Daiichi Sankyo. 1 trial record tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- Daiichi Sankyo
Trials
| Drug | Phase | Indication |
|---|---|---|
| Valemetostat Tosylate NCT04703192 | Phase 2 | Relapsed/Refractory Peripheral T-Cell Lymphoma |
Latest
No recent events.
Follow Valemetostat on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.